Skip to main content

Advertisement

SpringerLink
Log in

Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Objective

To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance.

Methods

Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL.

Results

Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53–88.57%) (n = 309) and 80% (CI 74.65–85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL).

Conclusions

QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mani, H., & Lindhoff-Last, E. (2014). New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design Development and Therapy, 8, 789–798.

    Article  CAS  Google Scholar 

  2. Potpara, T. S., Jokic, V., Medic, B., Prostran, M., & Lip, G. Y. (2015). An update on atrial fibrillation: focus on stroke risk reduction strategies. Minerva Medica, 106, 259–273.

    CAS  PubMed  Google Scholar 

  3. Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.

    Article  Google Scholar 

  4. de Andrés-Nogales, F., Oyagüez, I., Betegón-Nicolás, L., Canal-Fontcuberta, C., & Soto-Álvarez, J. (2015). Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp, 215, 73–82.

    Article  PubMed  Google Scholar 

  5. Camm, A. J., Lip, G. Y., de Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace, 14, 1385–413.

    Article  Google Scholar 

  6. Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.

    Article  Google Scholar 

  7. Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.

    Article  CAS  PubMed  Google Scholar 

  8. Newby, L. K., LaPointe, N. M., Chen, A. Y., Kramer, J. M., Hammill, B. G., DeLong, E. R., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212.

    Article  CAS  PubMed  Google Scholar 

  9. Amin, A., & Marrs, J. C. (2016). Direct oral anticoagulants for the management of thromboembolic disorders: The importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost, 22, 605–616.

    Article  PubMed  Google Scholar 

  10. Martinez, C., Katholing, A., Wallenhorst, C., & Freedman, S. B. (2016). Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost, 115, 31–39.

    Article  PubMed  Google Scholar 

  11. Gusmai Lde, F., Novato Tde, S., & Nogueira, Lde S. (2015). The influence of quality of life in treatment adherence of diabetic patients: a systematic review. Revista da Escola Enfermagem da USP, 49, 839–846.

    Article  Google Scholar 

  12. Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.

    Article  CAS  PubMed  Google Scholar 

  13. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883–891.

    Article  CAS  PubMed  Google Scholar 

  14. Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., et al. (2016). XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Europe Heart Journal, 37, 1145–1153.

    Article  Google Scholar 

  15. Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., et al. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Europe Heart Journal, 32, 2387–2394.

    Article  CAS  Google Scholar 

  16. Sawicki, P. T. (1999). A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA, 281, 145–150.

    Article  PubMed  Google Scholar 

  17. Sánchez González, R., Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., Alvarez Nido, R., & Barrera, Linares E. (2004). Adaptación transcultural de un cuestionario para medir la calidad de vida de los pacientes con anticoagulación oral. Atención Primaria, 34, 353–359.

    Article  CAS  PubMed  Google Scholar 

  18. Gadisseur, A. P., Kaptein, A. A., Breukink-Engbers, W. G., de Mol, B. J., Prins, M. H., Hutten, B. A., et al. (2004). Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: Positive effects on quality of life. Journal of Thrombosis and Haemostasis, 2, 584–591.

    Article  CAS  PubMed  Google Scholar 

  19. Siebenhofer, A., Hemkens, L. G., Rakovac, I., Spat, S., & Didjurgeit, U. (2012). Self-management of oral anticoagulation in elderly patients—effects on treatment-related quality of life. Thromb Res, 130, e60–e66.

    Article  CAS  PubMed  Google Scholar 

  20. Alegret, J. M., Viñolas, X., Arias, M. A., Martínez-Rubio, A., Rebollo, P., Ràfols, C., et al. (2014). New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. International Journal Medical Sciences, 11, 680–684.

    Article  Google Scholar 

  21. Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., & Sánchez, González R. (2005). Quality of life of patients treated with oral anticoagulants. Atencion Primaria, 36, 224–225.

    Article  CAS  PubMed  Google Scholar 

  22. De Schryver, E. L., van Gijn, J., Kappelle, L. J., Koudstaal, P. J., Algra, A., Dutch, T. I. A., et al. (2005). Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. Journal of Neurology, 252, 1316–1321.

    Article  PubMed  Google Scholar 

  23. Nelson, W. W., Song, X., Thomson, E., Smith, D. M., Coleman, C. I., Damaraju, C. V., et al. (2015). Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrilation. Current Medical Resarch and Opinion, 31, 1831–1840.

    Article  Google Scholar 

  24. Crivera, C., Nelson, W. W., Bookhart, B., Martin, S., Germain, G., Laliberté, F., et al. (2015). Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Current Medicine Resarch and Opinion, 31, 1889–1895.

    Article  Google Scholar 

  25. Ynsaurriaga, F. A., Peinado, R. P., & Ormaetxe Merodio, J. M. (2014). Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiology, 10, 381–393.

    Article  CAS  PubMed  Google Scholar 

  26. Cromheecke, M. E., Levi, M., Colly, L. P., De Mol, B. J. M., Prins, M. H., Hutten, B. A., et al. (2000). Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. The Lancet, 356, 97–102.

    Article  CAS  Google Scholar 

  27. Sawicki, P. T., Gläser, B., Kleespies, C., Stubbe, J., Schmitz, N., Kaiser, T., et al. (2003). Self-management of oral anticoagulation: long-term results. Journal of Internal Medicine, 254, 515–516.

    Article  CAS  PubMed  Google Scholar 

  28. Hasan, S. S., Teh, K. M., Ahmed, S. I., Chong, D. W., Ong, H. C., & Naina, B. (2015). Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health, 129, 954–962.

    Article  CAS  PubMed  Google Scholar 

  29. Fareau, S., Baumstarck, K., Farcet, A., Molines, C., Auquier, P., & Retornaz, F. (2015). Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants. Geriatrie et Psychologie Neuropsychiatrie du Vieillissement, 13, 45–54.

    PubMed  Google Scholar 

  30. Freeman, J. V., Simon, D. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., et al. (2015). Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circulation Cardiovascular Quality and Outcomes, 8, 393–402.

    Article  PubMed  Google Scholar 

  31. de Almeida, G., Noblat Lde, A., Passos, L. C., & do Nascimento, H. F. (2011). Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Quality Life Outcomes, 9, 91.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all the researchers of the CUMRIVAFA and the rest of the team of the SHE-LEHLA Compliance Study Group for their work. We thank to Bayer Hispania SL for their sponsorship in this study.

Funding

This study was funded by Bayer Healthcare (Grant 01-2014). Bayer gave a grant to the Association Medical Group Onuba, Huelva (Spain). This association was the promoter of the study.

Author information

Authors and Affiliations

  1. Unidad de Gestión Clínica La Orden, C/PUERTO, 6º D, 21003, Huelva, Spain

    Emilio Márquez-Contreras & Sara Márquez-Rivero

  2. Medicina Interna, Hospital San Carlos Madrid, Madrid, Spain

    Nieves Martell-Claros

  3. Universidad de Medicina, Elche, Alicante, Spain

    Vicente Gil-Guillén

  4. ABS Sardenya, Barcelona, Spain

    Mariano De la Figuera-Von Wichmann

  5. Centro Salud Puerto Santa María, Cadiz, Spain

    Eugenio Sánchez-López

  6. ABS Vieilla, Lleida, Spain

    Ines Gil-Gil

Authors
  1. Emilio Márquez-Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nieves Martell-Claros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vicente Gil-Guillén
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariano De la Figuera-Von Wichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugenio Sánchez-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ines Gil-Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sara Márquez-Rivero
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Working Group on Compliance and Inertia. Spanish Society of Hypertension

Corresponding author

Correspondence to Emilio Márquez-Contreras.

Ethics declarations

Conflict of interest

No conflict of interest existed. The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Clinical Ethics Committee of Andalucía, Elda and Jordi Gol i Gurina Foundation.

Informed consent

Informed consent was obtained from all individual participants included in the study. File attached informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Márquez-Contreras, E., Martell-Claros, N., Gil-Guillén, V. et al. Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Qual Life Res 26, 647–654 (2017). https://doi.org/10.1007/s11136-016-1489-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-016-1489-x

Keywords

Search

Navigation